FDA Approves Admelog, the First Short-acting “Follow-on” Insulin Product to Treat Diabetes

The U.S. Food and Drug Administration(FDA) approved Admelog (insulin lispro injection), a short-acting insulin indicated to improve control in blood sugar levels in adults and pediatric patients aged 3 years and older with type 1 diabetes mellitus and adults with type 2 diabetes mellitus. Admelog is the first short-acting insulin approved as a “follow-on” product (submitted through the agency’s 505(b)(2) pathway).

• Source: fda.gov
• 601
• December 13, 2017